Skip to content
    Clinical Trials

    Finotonlimab Plus SCT200 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Lin et alCancer Medicine

    Finotonlimab Plus SCT200 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    A prospective, multicenter, open-label Phase Ib trial evaluated the efficacy and safety of combining finotonlimab (a PD-1 antibody) with SCT200 (an EGFR antibody) in 41 patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study evaluated two patient populations: Cohort A (n = 11), consisting of patients previously treated with platinum-based chemotherapy and immune checkpoint inhibitors, and Cohort B (n = 30), comprising systemic therapy-naïve patients. Dosing consisted of finotonlimab at 200 mg every 3 weeks alongside SCT200 at 6 mg/kg weekly for 12 weeks, followed by 8 mg/kg every 2 weeks. The primary endpoint was objective response rate (ORR).
    The combination therapy showed promising activity, particularly in systemic therapy-naïve patients. In Cohort B, the ORR reached 56.7%, with a median progression-free survival (PFS) of 9.6 months and an estimated median overall survival (OS) of 13.6 months. Among previously treated patients in Cohort A, the ORR was 27.3%, with a median PFS of 5.8 months and a median OS of 10.6 months. Treatment-related adverse events were reported as manageable, with the most common being hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%).

    Key Takeaways

    • In systemic therapy-naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (Cohort B, n = 30), finotonlimab plus SCT200 achieved an objective response rate of 56.7%, a median progression-free survival of 9.6 months, and an estimated median overall survival of 13.6 months.
    • In patients previously treated with platinum chemotherapy and immune checkpoint inhibitors (Cohort A, n = 11), the combination yielded an objective response rate of 27.3%, a median progression-free survival of 5.8 months, and a median overall survival of 10.6 months.
    • Treatment-related adverse events were manageable, with the most frequent toxicities being hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%).